Fertility Company Achieves Significant Expansion in Clinic Revenue
INVO Bioscience (INVO) has released its financial results for the fourth quarter and fiscal year ended December 31, 2023, showcasing remarkable growth in revenue and clinic performance.
In Q4 2023, the company recorded revenue of $1,381,754, marking a substantial 397% increase compared to the same period in 2022. Clinic revenue saw an even more impressive surge, soaring by 519% to $1,362,938. Notably, revenue from all clinics, including those under the equity method, reached $1,634,912, a robust 140% increase year-on-year.
For the full year 2023, INVO Bioscience reported revenue of $3,020,575, reflecting a remarkable 267% growth compared to 2022. Clinic revenue surged by 366% to $2,862,574, demonstrating the company’s strong performance in fertility services.
Steve Shum, CEO of INVO Bioscience, expressed satisfaction with the company’s progress, highlighting their focus on capturing a greater share of the fertility cycle revenue. With a strategic vision to enhance accessibility to advanced fertility care, INVO remains optimistic about achieving profitability and sustained growth in the coming years.
Read original press release: here
You might like this article:United Airlines Adjusts Aircraft Deliveries Amid Boeing Crisis
